0001415889-24-014451.txt : 20240524
0001415889-24-014451.hdr.sgml : 20240524
20240524161004
ACCESSION NUMBER: 0001415889-24-014451
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240522
FILED AS OF DATE: 20240524
DATE AS OF CHANGE: 20240524
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yea Christopher
CENTRAL INDEX KEY: 0001691102
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 24984375
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE, BUILDING 200
STREET 2: SUITE 2203
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 200915291
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (857) 999-0075
MAIL ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Therapeutics, Inc.
DATE OF NAME CHANGE: 20140916
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
4
1
form4-05242024_080552.xml
X0508
4
2024-05-22
0001348911
KalVista Pharmaceuticals, Inc.
KALV
0001691102
Yea Christopher
C/O KALVISTA PHARMACEUTICALS, INC
55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE
MA
02142
false
true
false
false
CHIEF DEVELOPMENT OFFICER
0
Restricted Stock Units
2024-05-22
4
A
0
50000
0
A
Common Stock
50000
50000
D
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the vesting commencement date, commencing on August 22, 2024, until fully vested, subject to continued service through each vesting date.
/s/ Benjamin L. Palleiko, Attorney-in-Fact
2024-05-24